Introduction
Hepatic ¢brosis is an important consequence of in£ammatory disorders a¡ecting the liver, and ultimately progresses to cirrhosis. This leads to the complications of portal hypertension (bleeding oesophageal varices and ascites), liver failure and ultimately hepatocellular carcinoma. In this article, we explore methods for the detection and monitoring of hepatic ¢brosis, particularly in hepatitis C, alcoholic liver disease (ALD), nonalcoholic fatty liver disease (NAFLD) and during methotrexate therapy, in all of which progressive ¢brosis can develop over a number of years in a minority of patients.
Hepatic fibrosis
Hepatotropic viruses, alcohol, NAFLD, drugs and hepatic immune diseases are the leading causes of chronic liver diseases. Chronicity is characterized by the persistence of in£ammation and the development of ¢brosis. The in£ammatory process in the liver leads to the production of cytokines, chemokines and other signalling molecules, which lead to activation and transformation of quiescent lipocyte-rich stellate cells (Ito cells) into myo¢broblasts, which in turn are responsible for the production of excess extracellular matrix protein. 1 The matrix is a complex mixture of glycoproteins (collagen, elastin, ¢bronectin, laminin) and proteoglycan organized in a tridimensional network. Fibrogenesis lasts as long as injury persists in the liver, and is believed to help limit the extent of the in£ammatory reaction.When the hepatocellular injury persists, ¢brosis is progressive and ultimately leads to cirrhosis.
Liver biopsy is currently the gold standard for assessing ¢brosis. It provides a unique source of information on in£ammation, ¢brosis, steatosis, iron status and neoplasia of the liver. In viral hepatitis, for example, liver biopsy provides evidence of the severity of the disease necessary for treatment decisions, and for assessing drug e⁄cacy. However, liver biopsy has several limitations, including manpower issues, associated cost, risk of patient injury (including mortality and morbidity), observer variability and sampling variation. 2--5 There are several histological techniques for assessing ¢brosis in liver biopsies, including semiquantitative 6--10 and quantitative techniques. 11--16 Factors which improve the diagnostic accuracy of liver biopsy include quantitative techniques, the presence of uniform disease throughout the liver, multiple passes of a trucut needle (15 gauge) and biopsy of 2 cm or greater in length. 3, 17, 18 The most widely used systems for grading activity and staging ¢brosis are semi-quantitative (Ishak 9 and METAVIR 8 ). The Ishak system scores necro-in£ammatory activity from zero to 18, assessing portal and lobular in£ammation. Fibrosis is from zero to six. Scores one and two indicate portal ¢brosis, three and four indicate bridging ¢brosis, while ¢ve and six indicate incomplete and established cirrhosis, respectively. The METAVIR system has a four-point scale for in£ammation and a ¢ve-point scale for ¢brosis, as follows: chronic hepatitis without ¢brosis (F0); portal ¢brosis without septae (F1); portal ¢brosis with a few septae (F2); septal ¢brosis without cirrhosis (F3); complete cirrhosis (F4). The system has been validated and shows good intra-and inter-observer reproducibility. 5 The Brunt system 10 has been advocated for assessing morphological changes in non-alcoholic steatohepatitis. In these scoring systems assessment of ¢brosis is subjective, and it may be di⁄cult to compare the results between di¡erent studies using the di¡erent scoring systems. In research studies in ALD, NAFLD and viral hepatitis 12--14 quantitative techniques have therefore been used, and Zaitoun et al. 12 have shown a linear increase in the mean value of ¢brosis in comparison with the Ishak system 9 in liver biopsies from patients with chronic hepatitis C. However, a four-fold variation in the proportion of ¢brosis within the same groups of patients with established cirrhosis (stage 6) was reported. It is now known that, with the arrest of in£ammation after eradication of the hepatitis C virus, cirrhosis can be reversed. 19 
Non-invasive tests for hepatic fibrosis
Recently, several non-invasive diagnostic tests for ¢brosis and cirrhosis have been evaluated. These include echography, 20,21 transient elastography, 22 magnetic resonance imaging 23 and, most importantly, haematological 24--26 (in patients with portal hypertension platelet consumption is increased) and biochemical markers of liver ¢brosis. 27--58 An ideal non-invasive biomarker of liver ¢brosis should ful¢ll the following requirements:
Speci¢c for liver; Easy to perform in any laboratory; Re£ect the stage of ¢brosis; Be cost-e¡ective; The test should be standardized between labora-
tories;
Results should be independent of any associated in£ammation.
It is therefore important to perform clinical trials in di¡erent groups of patients with liver ¢brosis secondary to several aetiologies to identify speci¢c markers of ¢brosis before their use in clinical practice can be categorically recommended. Several biomarkers have been evaluated for sensitivity and speci¢city for ¢brosis and by the use of receiver operating curves (ROC) ( Figure 1 ) as follows:
(1) Apolipoprotein A1: the major protein found in high-density lipoprotein. The plasma concentration is negatively associated with ¢brosis. 27 Tissue sites of degradation are probably liver and kidney. Abnormalities of serum apolipoprotein A1 concentration are caused by diet, alcohol and drugs, and by metabolic, hormonal and infectious diseases. Reproduced from Naveau et al. 52 with the kind permission of Springer Science and Business Media. A score of 6 (max 16) indicates cirrhosis in 75% (sensitivity), but 23% with this score will not have cirrhosis (false positive).
(3) a-2-macroglobulin (AMG): a large intra-vascular protease inhibitor, synthesized in hepatocytes and hepatic stellate cells, which inhibits the catabolism of matrix proteins. Values thus correlate positively with the grade of ¢brosis. 52 (4) Glycosaminoglycan (hyaluronic acid): 28,30,37,54 a mucopolysaccharide present mainly in joints and some other tissues, which is degraded by the enzyme hyaluronidase. The serum level of hyaluronic acid is increased in chronic liver disease due to synthesis from ¢broblasts and stellate cells. A serum hyaluronate of o60 mg/L excluded cirrhosis and signi¢cant ¢brosis with predictive values of 99% and 93%, respectively. 37 (5) Collagen proteins: the serum level of pro-collagen peptides and type I, type III and type IV collagen proteins is increased in connective tissue diseases and liver ¢brosis. 50, 51 The collagen metabolite laminin is one of the main components of basement membrane. High serum levels have been reported in patients with ALD. 53 (6) Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio: 31 this ratio increases with the progression of liver disease, probably due to impaired clearance of AST by sinusoidal liver cells. A ratio 41 has good sensitivity and speci¢city for the diagnosis of cirrhosis, and when combined with the platelet count in hepatitis C patients, only a few are misclassi¢ed. 39, 55 Furthermore, the ratio correlates with the model of end-stage liver disease (MELD) and Child Pugh prognostic indices. A ratio 41.16 is associated with shorter survival. 55, 56 The ratio has also been used for separating non-alcoholic steato-hepatitis from ALD, when values o1 suggest the former, while values X2 suggest the latter. 57 The European Liver Fibrosis Group have recently identi¢ed an algorithm combining age, hyaluronic acid (HA), amino-terminal propeptide of type III collagen (PIIINP) and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1) to calculate a discriminant score for ¢brosis in a group of patients with liver disease of mixed aetiology 49 as follows: The value progressively rises with increasing ¢brosis from a minimal value of À3.5 to a maximum of 6.0 ( Figure 2) . For a threshold value of 0.102, 90% of patients with signi¢cant ¢brosis (grades 3 and 4) were detected (sensitivity), while absence of ¢brosis (negative predictive value of signi¢cant ¢brosis) was predicted in 92%.
Clinical use of biomarkers of fibrosis
Hepatitis C Several non-invasive techniques have been used to assess ¢brosis in chronic hepatitis C, which is now one of the leading causes of liver ¢brosis. The most important of these techniques which can be used to classify patients as having an early or advanced stage of ¢brosis are those of Imbert-Bismut et al., 29 Wai et al. 39 and Forns et al. 41 In the Imbert-Bismut FIBROTEST, 29 ¢ve biomarkers for ¢brosis were used (apolipoprotein A1, haptoglobin, AMG, gamma glutamyl transpeptidase [GGT] and total bilirubin; Figures 3 and 4) to predict hepatitis C-related ¢brosis, 38 and response to antiviral treatment. 58 Wai et al. 39 used the AST/platelet (APRI) ratio to study 270 treatment-na|« ve hepatitis C patients:
For patients with an Ishak score X3, the area under the ROC curve was 0.82.When the APRI score was less than 1.0, 98% were not cirrhotic. In the group with an APRI score of greater than 2.0, 57% were cirrhotic and there were only seven false positives. Two cuto¡ values were chosen from the ROC to identify absence (o4.2) and presence (46.9) of signi¢cant ¢brosis. The scoring system was validated in a separate group and showed that for patients without signi¢cant ¢brosis (stage F0/F1) the overall accuracy was 96%. However, it was not useful for identifying high levels of ¢brosis as only 10 of 33 patients with stage F2--F4 were identi¢ed by this scoring system. Patel et al. 35 used the FORNS index in 110 patients with chronic hepatitis C and reported that a score of less than 4.2 had a negative predictive value for ¢brosis of 89%, but 59% of patients could not be classi¢ed.
Thabut et al. 48 compared the FORNS index to the FIBROTEST in 476 untreated patients with chronic hepatitis C. Both the FIBROTEST and FORNS index were good at excluding ¢brosis, but the FIBROTEST had a greater positive predictive value (90%) for diag-nosis of advanced ¢brosis. The FIBROTEST has several advantages over the FORNS index. First, it is not viral genotype dependent (genotype 3 patients have lower cholesterol levels than genotype 1). Second, the FORNS test includes platelet count, which is poorly standardized between laboratories. Third, the FIBROTEST has been validated in another group of patients, such as patients with AIDS. 45 Fourth, a combination of ALT levels and the FIBROTEST accurately predicts the severity of necro-in£ammatory activity. In an Australian series, the negative predictive value for signi¢cant ¢brosis of a FIBROTEST score of o0.1 was 85%, the positive predictive value of a score of 40.6 was 78%, while about 20% of those who could have avoided liver biopsy were misclassi¢ed. 42 In a recent study, Patel et al. 35 used the combined markers HA,TIMP-1 and AMG and were able to di¡erentiate F0/F1 from F2/F4, while the number of patients in the indeterminate group was 28--30%.
Alcoholic liver disease
Non-invasive tests were initially used to assess ¢brosis in ALD. 27, 28 Naveau et al. 52 found that the prothrombin time, GGT, Apolipoprotein A1 (PGA) index was a useful marker of liver ¢brosis in ALD, while the addition of AMG improved discriminant function and was correlated positively with the grade of ¢brosis, whatever the degree of steatosis or alcoholic hepatitis on liver biopsy (Figure 3 ). Oberti et al. 47 found that serum hyaluronate concentration was the most sensitive marker in groups of patients with viral hepatitis and ALD, and correctly diagnosed cirrhosis in 91--94% of these groups of patients. A cuto¡ value of X60 mg/L had a sensitivity of 97% and speci¢city of 73%. When combined with prothrombin index, 90% can be correctly classi¢ed according to the severity of liver ¢brosis, 44 Figure 3 Concentrations of a-2-macroglobulin and haptoglobin in each stage of fibrosis (Metavir). 29 Reproduced from Imbert-Bismut et al. 29 with permission from Elsevier. 
Non-alcoholic fatty liver disease
This is now the most common cause of liver dysfunction, as determined by liver function testing, and it has been estimated that with increasing levels of obesity in the USA 20 million patients are a¡ected. Although simple hepatic steatosis can be a benign non-progressive condition, the natural history ranges from indolent to end-stage cirrhosis, and the latter is thought to have the morphological features of non-alcoholic steatohepatitis (NASH). The histological features of NASH can mimic those of ALD. 59, 60 In NASH patients, the in£ammatory process leads to progression of ¢brosis with bridging septal formation and the development of cirrhosis. 59 In NASH patients with bridging ¢brosis or cirrhosis, 49% had an AST/ALT ratio 41, and this ¢gure was 66% in those who were also X45 years old, diabetic and obese. 61 
Monitoring drug hepatotoxicity
Many drugs can induce hepatotoxicity, either directly by inducing liver cell injury or indirectly as the result of systemic reaction leading to allergic hepatotoxic injury. Liver ¢brosis may develop in a small proportion of psoriatic patients treated with methotrexate, 62 and non-steroidal anti-in£ammatory drugs. 63 In psoriasis, liver enzyme abnormalities are regarded as an unreliable indicator of liver damage, and liver biopsy has been used to assess the progression of ¢brosis and improvement of liver abnormalities after cessation of treatment. 64 However, in a recent study Record and associates 65 found that monitoring liver biopsy in patients treated with methotrexate has little impact on patients' management and is no longer justi¢ed, unless 45 g of the drug had been administered, when the cumulative probability of developing advanced hepatic ¢brosis (Ishak X4) becomes 8.2%. In a 10-year followup study, Zachariae et al. 66 found that no liver ¢brosis was missed in 63 patients with consistently normal serum levels of type III procollagen. Methotrexate is also used in patients with rheumatoid arthritis and Crohn's disease, 67 particularly those who are resistant to other forms of treatment. Non-invasive tests of ¢brosis may also be valuable for monitoring for hepatic ¢brosis in these groups, although the presence of in£ammation in the joints or intestine may modify the results of the markers used and validation studies are required.
Conclusion
A clinically relevant non-invasive test to assess ¢brosis in patients with chronic liver diseases is of particular importance in the following circumstances:
(1) To assess the value of anti-¢brotic agents in future clinical trials.
(2) To di¡erentiate patients with progressive liver disease from those running a benign course, when the likelihood of disease progression is low (e.g. NAFLD). (3) For monitoring drug therapy, when the administered drug can cause hepatic ¢brosis (e.g. methotrexate).
The usefulness of laboratory tests for screening for a pathological abnormality such as ¢brosis is critically dependent on the prevalence of the pathology in the population under investigation. 68 In (1) above, the prevalence of ¢brosis is likely to be high, while in (2) and (3) a low prevalence is to be expected. Screening tests for the latter groups should have a high negative predictive value, so that large numbers of patients can be spared the next diagnostic step, namely liver biopsy. Some chronic liver diseases may be due to a complex aetiology. In such cases liver biopsy, even with all the disadvantages mentioned above, provides essential diagnostic information, which biomarkers, although valuable for assessing liver ¢brosis, cannot provide. Thus, liver biopsy will always remain an essential part of hepatological practice. However, its use for screening and the assessment of disease progression is likely to diminish as biomarker scores become more freely available. The cuto¡ values for the individual or combined components of the FIBROTEST have not been released into the public domain, but the calculation from individual patients results can be purchased in Europe from Biopredictive. In the USA, the analysis and results are available from blood samples submitted to Labcorp. In the meantime, as part of their routine service for monitoring the development of hepatic ¢brosis in patients with hepatitis C, NAFLD and those receiving methotrexate, clinical chemistry laboratories should o¡er: AST/ALT ratio; APRI ratio; The Rosenberg ¢brosis index 49 (the components of which are all commercially available).
